Zu, Youli

Publications

Sort by

Co-Author Network

selected publications

Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy. Theranostics. 2017 Academic Article GET IT
Times cited: 15
RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging. 2016 Academic Article GET IT
Times cited: 21
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 53
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 2016 Academic Article GET IT
Times cited: 41
Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2016 Academic Article GET IT
Times cited: 34
B7-H4 expression in ovarian serous carcinoma: a study of 306 cases. Human pathology. 2016 Academic Article GET IT
Times cited: 27
p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging. 2016 Academic Article GET IT
Times cited: 18
ssDNA Aptamer Specifically Targets and Selectively Delivers Cytotoxic Drug Doxorubicin to HepG2 Cells. PloS one. 2016 Academic Article GET IT
Times cited: 12
Aptamers: versatile molecular recognition probes for cancer detection. The Analyst. 2016 Review GET IT
Times cited: 80
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015 Academic Article GET IT
Times cited: 34
A unique aptamer-drug conjugate for targeted therapy of multiple myeloma. Leukemia. 2015 Letter GET IT
Times cited: 43
Mutated genes and driver pathways involved in myelodysplastic syndromes—a transcriptome sequencing based approach. Molecular bioSystems. 2015 Academic Article GET IT
Times cited: 9
Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials. 2015 Academic Article GET IT
Times cited: 86
A Highlight of Recent Advances in Aptamer Technology and Its Application. Molecules (Basel, Switzerland). 2015 Review GET IT
Times cited: 219
Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015 Academic Article GET IT
Times cited: 17
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?. Oncotarget. 2015 Academic Article GET IT
Times cited: 36
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Academic Article GET IT
Times cited: 70
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget. 2015 Academic Article GET IT
Times cited: 57
Aptamers and their applications in nanomedicine. Small (Weinheim an der Bergstrasse, Germany). 2015 Review GET IT
Times cited: 119
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2014 Academic Article GET IT
Times cited: 76
SDF-1α stiffens myeloma bone marrow mesenchymal stromal cells through the activation of RhoA-ROCK-Myosin II. International journal of cancer. 2014 Academic Article GET IT
Times cited: 11
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 62
A cancer cell-activatable aptamer-reporter system for one-step assay of circulating tumor cells. Molecular therapy. Nucleic acids. 2014 Academic Article GET IT
Times cited: 38
Oligonucleotide aptamers: new tools for targeted cancer therapy. Molecular therapy. Nucleic acids. 2014 Academic Article GET IT
Times cited: 398
Hand-held and integrated single-cell pipettes. Journal of the American Chemical Society. 2014 Academic Article GET IT
Times cited: 46
Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. International journal of cancer. 2014 Academic Article GET IT
Times cited: 15
Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes. Theranostics. 2014 Academic Article GET IT
Times cited: 33
A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2014 Academic Article GET IT
Times cited: 18
High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells. British journal of haematology. 2014 Academic Article GET IT
Times cited: 10
Enteropathy-associated T-cell lymphoma, type II (monomorphic variant). 2014 GET IT
Times cited: 2
Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers. The international journal of biochemistry & cell biology. 2014 Academic Article GET IT
Times cited: 18
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Academic Article GET IT
Times cited: 31
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 111
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 383
Automatic B cell lymphoma detection using flow cytometry data. BMC genomics. 2013 Academic Article GET IT
Times cited: 6
Biostable ssDNA aptamers specific for Hodgkin lymphoma. Sensors (Basel, Switzerland). 2013 Academic Article GET IT
Times cited: 6
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Academic Article GET IT
Times cited: 42
Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. Biomaterials. 2013 Academic Article GET IT
Times cited: 66
A berberine-loaded electrospun poly-(epsilon-caprolactone) nanofibrous membrane with hemostatic potential and antimicrobial property for wound dressing. Journal of biomedical nanotechnology. 2013 Academic Article GET IT
Times cited: 19
An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small (Weinheim an der Bergstrasse, Germany). 2013 Academic Article GET IT
Times cited: 61
Detecting circulating tumor cells: current challenges and new trends. Theranostics. 2013 Review GET IT
Times cited: 283
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Academic Article GET IT
Times cited: 34
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Academic Article GET IT
Times cited: 544
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Academic Article GET IT
Times cited: 188
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012 Academic Article GET IT
Times cited: 269
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2012 Academic Article GET IT
Times cited: 135
Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system. American journal of clinical pathology. 2012 Academic Article GET IT
Times cited: 24
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012 Academic Article GET IT
Times cited: 280
A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes. Molecular bioSystems. 2012 Academic Article GET IT
Times cited: 16
Transfecting the hard-to-transfect lymphoma/leukemia cells using a simple cationic polymer nanocomplex. Journal of controlled release : official journal of the Controlled Release Society. 2012 Academic Article GET IT
Times cited: 35
Multiplexed volumetric bar-chart chip for point-of-care diagnostics. Nature communications. 2012 Academic Article GET IT
Times cited: 177
NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis. Oncogene. 2011 Academic Article GET IT
Times cited: 30
Interleukin-2 Functions in Anaplastic Large Cell Lymphoma Cells through Augmentation of Extracellular Signal-Regulated Kinases 1/2 Activation. International journal of biomedical science : IJBS. 2011 Academic Article GET IT
A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. Journal of nanobiotechnology. 2011 Academic Article GET IT
Times cited: 65
Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo. Molecular cancer therapeutics. 2010 Academic Article GET IT
Times cited: 10
Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate gene expression in lymphoma cells. Gene therapy. 2010 Academic Article GET IT
Times cited: 44
Combination of an aptamer probe to CD4 and antibodies for multicolored cell phenotyping. American journal of clinical pathology. 2010 Academic Article GET IT
Times cited: 30
Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. Stem cells and development. 2010 Academic Article GET IT
Times cited: 34
Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2010 Academic Article GET IT
Times cited: 58
Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy. 2010 GET IT
Times cited: 11
Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126. Cancer gene therapy. 2010 Academic Article GET IT
Times cited: 17
Unique biomechanical interactions between myeloma cells and bone marrow stroma cells. Progress in biophysics and molecular biology. 2009 Review GET IT
Times cited: 12
Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. Laboratory investigation; a journal of technical methods and pathology. 2009 Academic Article GET IT
Times cited: 60
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leukemia research. 2009 Academic Article GET IT
Times cited: 40
p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes. American journal of clinical pathology. 2008 Academic Article GET IT
Times cited: 12
Acute leukemia immunohistochemistry: a systematic diagnostic approach. Archives of pathology & laboratory medicine. 2008 Review GET IT
Times cited: 31
P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. British journal of haematology. 2008 Academic Article GET IT
Times cited: 45
Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Archives of pathology & laboratory medicine. 2007 Academic Article GET IT
Times cited: 24
Primary central nervous system histiocytic sarcoma with relapse to mediastinum: a case report and review of the literature. 2007 GET IT
Times cited: 47
Polycythemia vera: new clinicopathologic perspectives. Archives of pathology & laboratory medicine. 2006 Review GET IT
Times cited: 24
Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Archives of pathology & laboratory medicine. 2006 Academic Article GET IT
Times cited: 31
Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. Leukemia & lymphoma. 2005 Academic Article GET IT
Times cited: 45
Ultrafast Papanicolaou stain and cell-transfer technique enhance cytologic diagnosis of Hodgkin lymphoma. Diagnostic cytopathology. 2002 Academic Article GET IT
Times cited: 16
Ultrastructurally "invasive" microvilli in an aggressively metastasizing biphasic malignant mesothelioma. 2002 GET IT
Times cited: 6
Light microscopic and ultrastructural evidence of in vivo phagocytosis of Helicobacter pylori by neutrophils. Ultrastructural pathology. 2000 Academic Article GET IT
Times cited: 22
Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. The American journal of physiology. 1998 Academic Article GET IT
Times cited: 168
p38 mitogen-activated protein kinase activation is required for human neutrophil function triggered by TNF-alpha or FMLP stimulation. Journal of immunology (Baltimore, Md. : 1950). 1998 Academic Article GET IT
Times cited: 318
High expression and activation of MAP kinase-activated protein kinase 2 in cardiac muscle cells. Journal of molecular and cellular cardiology. 1997 Academic Article GET IT
Times cited: 39
Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts. FEBS letters. 1996 Academic Article GET IT
Times cited: 228
Preconditioning potentiates molecular signaling for myocardial adaptation to ischemia. Annals of the New York Academy of Sciences. 1996 Academic Article GET IT
Times cited: 26
Activation of MAP kinase-activated protein kinase 2 in human neutrophils after phorbol ester or fMLP peptide stimulation. Blood. 1996 Academic Article GET IT
Times cited: 67
A synthetic peptide containing a predominant protein kinase C site within p47phox inhibits the NADPH oxidase in intact neutrophils. Journal of leukocyte biology. 1996 Academic Article GET IT
Times cited: 15
Characterization of an autoinhibitory domain in human mitogen-activated protein kinase-activated protein kinase 2. The Journal of biological chemistry. 1995 Academic Article GET IT
Times cited: 37
The primary structure of a human MAP kinase activated protein kinase 2. Biochemical and biophysical research communications. 1994 Academic Article GET IT
Times cited: 44
Regulation of trans-activating capacity of CRE-BPa by phorbol ester tumor promoter TPA. Oncogene. 1993 Academic Article GET IT
Times cited: 19
Isolation and characterization of a novel member of the gene family encoding the cAMP response element-binding protein CRE-BP1. The Journal of biological chemistry. 1993 Academic Article GET IT
Times cited: 61
Transcriptional regulation by a point mutant of adenovirus-2 E1a product lacking DNA binding activity. The Journal of biological chemistry. 1992 Academic Article GET IT
Times cited: 20
Human T cell L-plastin bundles actin filaments in a calcium-dependent manner. Journal of biochemistry. 1992 Academic Article GET IT
Times cited: 119
Human glioma-specific antigens detected by monoclonal antibodies. Neurosurgery. 1992 Academic Article GET IT
Times cited: 14
Complete putative metal finger and leucine zipper structures of CRE-BP1 are required for the E1A-induced trans-activation. The Journal of biological chemistry. 1991 Academic Article GET IT
Times cited: 14
65-kilodalton protein phosphorylated by interleukin 2 stimulation bears two putative actin-binding sites and two calcium-binding sites. Biochemistry. 1990 Academic Article GET IT
Times cited: 33
Characterization of interleukin 2 stimulated 65-kilodalton phosphoprotein in human T cells. Biochemistry. 1990 Academic Article GET IT
Times cited: 29
Detection of fos oncogene products by monoclonal antibody FO-120 in lymphoproliferative disorders. Leukemia research. 1989 Academic Article GET IT
Times cited: 3
Persistent and enhanced expression of c-fos gene products in various kinds of human hematopoietic cell lines. Immunofluorescence study using prepared monoclonal antibodies. Acta pathologica japonica. 1988 Academic Article GET IT
Times cited: 3
Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse gamma-interferon complementary DNA. Cancer research. 1988 Academic Article GET IT
Times cited: 27

more ...

less ...

Background

education and training

Ph.D., Kyoto University (Japan) 1990
B.M., Jilin Medical College (China) 1982

Contact

full name

Youli Zu

VIVO Weill Cornell Medical College

Youli Zu Professor of Pathology and Laboratory Medicine

Publications

selected publications

Background

education and training

Contact

full name